China National Pharmaceutical Group (Sinopharm) produced an experimental Coronavirus vaccine that has 86% efficacy. The Health Ministry of the United Arab Emirates informed the information while summoning an interim analysis of late-stage clinical trials on Wednesday.
Companies like Pfizer Inc, Moderna, AstraZeneca Plc have already given the positive data last month, but neither UAE nor Sinopharm has released detailed data from the pivotal study. According to a Reuters report, the Gulf Arab state started Phase III clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG) in July. This leading to the permission of the emergency use of the vaccine for certain groups in September.
The ministry stated in a statement carried by the state news agency. The analysis showed a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease, and the research shows no severe safety concerns. Even the vaccine’s official registration has already begun with 31000 volunteers across the 125 nationalities participated in the UAE trail.
They didn’t inform about any side effects by chance identified and regarding the number of participants who have become ill and the details of volunteers who were given the vaccine.
The UAE trial is a partnership between CNBG, Abu Dhabi-based artificial intelligence company Group 42 (G42), and the Abu Dhabi Department of Health.